SSTR5
SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Overview
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Pasireotide. Open Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.81, genetic association 0.00, clinical 0.91). In OnCo, 1 product record names it (Pasireotide).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
- 1 · What it is
SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
- 2 · What goes wrong in cancer
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
- 3 · How drugs use it
No product in this corpus aims at SSTR5 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:11334 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35346 (protein name, function text, keywords and locations (REST API)); CIViC gene SSTR5 (1 evidence items, 0 assertions, 2 variants; diseases: Neuroendocrine Tumour (GraphQL API, CC0)); Open Targets ENSG00000162009 (association with cancer (MONDO_0004992) 0.58; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.60 (GraphQL API, CC0))
Biology
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation. Location: Cell membrane (UniProt). Locus 16p13.3 (HGNC).
- Neuroendocrine tumours: Open Targets association 0.60 with neuroendocrine neoplasm (MONDO_0019496); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SSTR5" OR ABSTRACT:"SSTR5" OR TITLE:"somatostatin receptor 5" OR ABSTRACT:"somatostatin receptor 5" OR TITLE:"Somatostatin receptor type 5" OR ABSTRACT:"Somatostatin receptor type 5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSTR5, not a curated reading list.